This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PAT-001

Almirall Prodesfarma, S.A.

Description: PAT-001 acts as a keratolytic agent for the treatment of skin disorders associated with hyperkeratinization.

Deal Structure: Almirall and Patagonia
In July 2016, Almirall announced that it has entered through US-based Aqua into a global licensing agreement with Patagonia Pharmaceuticals for the development and commercialization of PAT-001.

Partners: Patagonia Pharmaceuticals, LLC


PAT-001 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug